Platinum resistant ovarian cancer orr

Author: tvfv

August undefined, 2024

Webb5 jan. 2024 · Abstract Purpose: Platinum-resistant ovarian cancer (PROC) is usually treated with single-agent chemotherapy. A synergistic effect of gemcitabine and platinum has … Webb15 dec. 2024 · Two phase II trials have tested this concept in people with platinum-resistant and unresponsive ovarian cancer. One, run by Dana-Farber and NCI …

Bevacizumab Combined With Weekly Paclitaxel, Pegylated …

WebbPurpose: Single-agent chemotherapies have limited activity and considerable toxicity in patients with platinum-resistant epithelial ovarian cancer (PROC). Mirvetuximab … WebbIntroduction. Epithelial ovarian cancer (EOC) is the leading cause of death from gynecological malignancy in the Western World. It is the seventh most common cancer … cytocompatibilities

Efficacy of cisplatin combined with topotecan in patients... : …

WebbObjective: Our objective was to assess safety and adverse events associated with intraperitoneal Olvi-Vec virotherapy in patients with platinum-resistant or refractory … WebbProgression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PROs) were significantly improved by adding bevacizumab to chemotherapy … WebbVirus-induced changes in the tumor microenvironment may explain the apparent reversal of platinum resistance. Clinical trial identification NCT02759588. Editorial acknowledgement None. Legal entity responsible for the study Genelux Corporation, San Diego, CA, USA. Funding Genelux Corporation, San Diego, CA, USA. Disclosure cytocomp cells

Platinum rechallenge treatment using gemcitabine plus ... - PubMed

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian …

Webb13 apr. 2024 · The ORR of platinum-resistance recurrent patients in this study was 39%. Among these 41 patients, 26.8% ... Which non-platinum single agent combined with bevacizumab has better efficacy in the treatment of platinum-resistant recurrent ovarian cancer needs to be further verified by randomized controlled trials with a larger sample … Webb8 juni 2024 · Patients must have platinum resistant high grade serous carcinoma of ovarian, fallopian tube or peritoneal origin defined as progression within 6 months of last platinum containing chemotherapy. Histological confirmation of the original primary tumour is required. All patients must have measurable disease as defined by RECIST 1.1. cytocrine secretionWebb1 aug. 2024 · Objectives: Patients with platinum-resistant recurrent ovarian cancer lack effective treatment. This phase II study (ChiCTR2000029654) was conducted to evaluate … cytochrome diagnostic tests

"Webb1 juni 2024 · Purpose: Single-agent PD-1 blockade exhibits limited efficacy in epithelial ovarian cancer (EOC). We evaluated ipilimumab plus nivolumab compared with nivolumab alone in women with persistent or recurrent EOC. Methods: Eligibility criteria included measurable disease, 1-3 prior regimens, and platinum-free interval (PFI) < 12 months. " - Platinum resistant ovarian cancer orr

Platinum resistant ovarian cancer orr

Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm …

Webb25 mars 2024 · The agent also has been evaluated in combination with bevacizumab in the platinum-resistant, recurrent ovarian cancer setting. In a phase 1b trial, data showed that the ADC led to an ORR... Webb17 mars 2014 · Purpose In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab is active alone and in combination. AURELIA is the first randomized phase III trial to our knowledge combining bevacizumab with chemotherapy in platinum-resistant OC. Patients and Methods Eligible patients had …

Did you know?

Webb8 jan. 2024 · Even though 80% of patients with High-Grade Serous Ovarian Cancer respond to standard first-line chemotherapy, a majority of them could relapse in the following five years due to a resistance to platinum. Human Epididymis protein 4 (HE4) is one of the most promising markers in predicting platinum therapy response. This pilot study aims … Webb20 mars 2024 · Liu noted that the majority of patients enrolled had BRCA wt or HRRwt tumors, and that 43.9% of patients had platinum-resistant disease, both of which are predictive factors associated with...

Webb14 apr. 2024 · Survival outcomes for patients with advanced ovarian cancer remain poor despite advances in chemotherapy and surgery. Platinum-based systemic chemotherapy … WebbIn the platinum-resistant cohort, the ORR was 43.3%, 93.3% cases had clinical benefit and the duration of response was 5.5 months. Ten cases ... Platinum-resistant ovarian …

WebbDNA damage repair (DDR) defects are common in different cancer types, and these alterations can be exploited therapeutically. Epithelial ovarian cancer (EOC) is among the … WebbBackground: Licensed systemic treatment options for platinum-sensitive recurrent ovarian cancer are platinum-based chemotherapy and maintenance treatment with bevacizumab …

Webb23 juli 2024 · “We are very encouraged by the potential of AVB-500 to improve responses and progression free survival in combination with chemotherapy in platinum resistant ovarian cancer. The information we have obtained from the clinical data together with some informal preliminary feedback from the FDA have helped inform our Phase 2/3 trial …

Webb11 apr. 2024 · BackgroundThere are a variety of treatment options for recurrent platinum-resistant ovarian cancer, and the optimal specific treatment still remains to be determined. Therefore, this Bayesian network meta-analysis was conducted to investigate the optimal treatment options for recurrent platinum-resistant ovarian cancer.MethodsPubmed, … cytogam approval dateWebbORR for single-agent chemotherapy reported in prior trials of PROC, which range from 4% to 13%.4-12 ... Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum … cytocompatible definitionWebbPlatinum chemotherapy remains the cornerstone of treatment for epithelial ovarian cancer (OC) and Poly (ADP-ribose) polymerase inhibitors (PARPi) now have an established role … cytodiagnostics g-20-20WebbApatinib is an oral and highly potent tyrosine-kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2). 5 Efficacy and safety of apatinib in patients with platinum-resistant recurrent epithelial ovarian cancer (PROC) were shown in phase II clinical trials. 6 Besides, apatinib combined with oral etoposide was proved to be … cytodifferentiation defineWebb31 juli 2024 · About Ovarian Cancer Each year in the United States, more than 22,000 women develop ovarian cancer and there are approximately 14,240 attributed deaths annually, making ovarian cancer the deadliest of gynecologic malignancies. Clinical studies over time have shown little response to treatment, especially for platinum-resistant … cytodifferentiationWebb29 juni 2024 · Women with platinum-resistant or refractory relapsed epithelial ovarian cancer continue to have a poor prognosis, and effective treatment of platinum … cytochrome p450 enzyme inhibitorsWebb14 sep. 2024 · Patients must be considered platinum-resistant, defined as progression within 6 months from completion of a platinum-containing therapy Patient must be considered appropriate for treatment with weekly paclitaxel monotherapy as … cytodiagnostics社